Deutsch English Français

Contact

EP2408449

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2408449

EP2408449 - METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 18.11.2016 Database last updated on 02.11.2024
Most recent event Tooltip	18.11.2016	Application deemed to be withdrawn	published on 21.12.2016 [2016/51]
Applicant(s)	For all designated states The Board Of Trustees Of The University Of the Leland Stanford Junior University 1705 El Camino Real Palo Alto, CA 94306-1106 / US
	For all designated states Eiger Biopharmaceuticals, Inc. 3350 W. Bayshore Road, Suite 120 Palo Alto, CA 94303 / US
	[N/P]
Former [2012/04]	For all designated states The Board Of Trustees Of The University Of the Leland Stanford Junior University 1705 El Camino Real Palo Alto, CA 94306-1106 / US
	For all designated states Eiger Biopharmaceuticals, Inc. 3350 W. Bayshore Road, Suite 120 Palo Alto, CA 94303 / US
Inventor(s)	01 / CHOONG, Ingrid, C. 3350 W. Bayshore Rd. Suite 120 Palo Alto, CA 94303 / US
	02 / CORY, David 1541 Morse Blvd. San Carlos CA 94070 / US
	03 / GLENN, Jeffrey, S. 1130 Welch Rd., 336 Palo Alto CA 94304 / US
	04 / YANG, Wenjin 383 Bodega St. Foster City CA 94404 / US
	[2012/04]
Representative(s)	Vidon Brevets & Stratégie 16B, rue de Jouanet BP 90333 35703 Rennes Cedex 7 / FR
	[N/P]
Former [2014/42]	Marollé, Patrick Pierre Pascal, et al Cabinet Vidon Technopôle Atalante 16B, rue Jouanet BP 90333 35703 Rennes Cedex 7 / FR
Former [2012/04]	Larcher, Dominique Cabinet Vidon, 16 B, rue Jouanet, BP 90333 Technopole Atalante 35703 Rennes Cedex 7 / FR
Application number, filing date	10753954.6	16.03.2010
	WO2010US27400
Priority number, date	US20090383030	18.03.2009 Original published format: US 383030
	US20090383071	18.03.2009 Original published format: US 383071
	US20100299886P	29.01.2010 Original published format: US 299886 P
	[2012/04]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2010107739
	Date:	23.09.2010
	Language:	EN
	[2010/38]
	Type:	A2 Application without search report
	No.:	EP2408449
	Date:	25.01.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 23.09.2010 takes the place of the publication of the European patent application.
	[2012/04]
Search report(s)	International search report - published on:	KR	10.03.2011
	(Supplementary) European search report - dispatched on:	EP	10.07.2012
Classification	IPC:	A61K31/4184, A61K31/437, A61K31/4178, A61K31/337, A61K31/4965, A61P31/12	[2012/04]
	CPC:	A61K31/4184 (EP,US); A61K31/437 (EP,US); A61K31/4965 (EP,US); A61K45/06 (EP,US); A61P31/12 (EP); A61P31/14 (EP); (+) C07D235/06 (EP,US); C07D235/08 (EP,US); C07D235/10 (EP,US); C07D235/14 (EP,US); C07D235/16 (EP,US); C07D235/28 (EP,US); C07D401/04 (EP,US); C07D401/06 (EP,US); C07D401/12 (EP,US); C07D401/14 (EP,US); C07D403/06 (EP,US); C07D403/14 (EP,US); C07D405/06 (EP,US); C07D409/06 (EP,US); C07D413/06 (EP,US); C07D417/04 (EP,US); C07D471/08 (EP,US); C07D491/04 (EP,US) (-)
	C-Set:	A61K31/4184, A61K2300/00 (EP,US); A61K31/437, A61K2300/00 (US,EP); A61K31/4965, A61K2300/00 (US,EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/04]
Title	German:	VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON FLAVIVIRIDAE-VIRUSINFEKTIONEN	[2012/04]
	English:	METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION	[2012/04]
	French:	MÉTHODES ET COMPOSITIONS POUR TRAITER L'INFECTION PAR UN VIRUS DE LA FAMILLE DES FLAVIVIRIDAE	[2012/04]
Entry into regional phase	18.10.2011	National basic fee paid
	18.10.2011	Search fee paid
	18.10.2011	Designation fee(s) paid
	18.10.2011	Examination fee paid
Examination procedure	18.10.2011	Examination requested [2012/04]
	25.01.2013	Amendment by applicant (claims and/or description)
	19.04.2013	Despatch of a communication from the examining division (Time limit: M06)
	18.10.2013	Reply to a communication from the examining division
	16.05.2014	Despatch of a communication from the examining division (Time limit: M06)
	31.10.2014	Reply to a communication from the examining division
	05.02.2015	Despatch of a communication from the examining division (Time limit: M06)
	25.06.2015	Reply to a communication from the examining division
	25.09.2015	Despatch of a communication from the examining division (Time limit: M04)
	28.12.2015	Reply to a communication from the examining division
	07.03.2016	Despatch of a communication from the examining division (Time limit: M04)
	19.07.2016	Application deemed to be withdrawn, date of legal effect [2016/51]
	16.08.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/51]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.04.2013
Fees paid	Renewal fee
	30.03.2012	Renewal fee patent year 03
	27.03.2013	Renewal fee patent year 04
	25.03.2014	Renewal fee patent year 05
	23.03.2015	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.03.2016	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[YP]US2010028299 (EINAV SHIRIT [US], et al) [YP] 1-3,7-14 * the whole document *;
		[YP]WO2009039248 (UNIV STANFORD [US], et al) [YP] 1-3,7-14 * the whole document *;
		[X]US4011322 (RAHTZ DIETER, et al) [X] 1,2,4,8,10 * abstract *;
		[X]WO03060475 (NEUROGEN CORP [US], et al) [X] 1 * page 39; compound 15 *;
		[X]WO2006010446 (7TM PHARMA AS [DK], et al) [X] 1 * page 48; example 23 *;
		[X]WO2007115077 (ASTRAZENECA AB [SE], et al) [X] 1 * page 84; example 26.3 *;
		[XYI] - EINAV SHIRIT ET AL, "Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 26, no. 9, doi:10.1038/NBT.1490, ISSN 1087-0156, (20080901), pages 1019 - 1027, (20080831), XP002597121 [X] 4 * page 1022 - page 1024 * [Y] 1-3,7-14 [I] 1-3,7-14 DOI: http://dx.doi.org/10.1038/NBT.1490
		[X] - CAROTI P ET AL, "Synthesis, antilipidemic and platelet antiaggregatory activity of 2-aminobenzimidazole amide derivatives", IL FARMACO, ELSEVIER FRANCE * EDITIONS SCIENTIFIQUES ET MEDICALES, IT, (19890101), vol. 44, no. 3, ISSN 0014-827X, pages 227 - 255, XP008128293 [X] 1 * compound X (Scheme 1) *
		[A] - TUNCBILEK M ET AL, "SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF SOME NEW ANILINO BENZIMIDAZOLES", ARCHIV DER PHARMAZIE, WILEY - VCH VERLAG GMBH & CO. KGAA, DE, (19971201), vol. 330, no. 12, doi:10.1002/ARDP.19973301203, ISSN 0365-6233, pages 372 - 376, XP001064267 [A] 1 * compounds 13,5 * DOI: http://dx.doi.org/10.1002/ardp.19973301203
	International search	[Y]US4011322 (RAHTZ DIETER, et al);
		[A]WO2005012288 (GENELABS TECH INC [US], et al);
		[A]US6211177 (SPERL GERHARD [US], et al);
		[A]KR950031074 (ELI LILLY AND COMPANY);
		[A]US5552426 (LUNN WILLIAM H W [US], et al);
		[XP]WO2009039248 (UNIV STANFORD [US], et al)
		[Y] - BEAULIEU,C. ET AL., "Benzimidazoles as new potent and selective DP antagonists for the treatment of allergic rhinitis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2004), vol. 14, pages 3195 - 3199, XP004841373 DOI: http://dx.doi.org/10.1016/j.bmcl.2004.04.005
		[Y] - EINAV,S. ET AL., "Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis", NATURE BIOTECHNOLOGY, (200809), vol. 26, no. 9, pages 1019 - 1027, XP002597121 DOI: http://dx.doi.org/10.1038/NBT.1490
	by applicant	US3470194
		US4692147
		US4360019
		US4487603
		US4725852
		US5820589
		US5643207
		US6198966
		WO9727840
		US5985305
		US5728396
		US3760984
		US3845770
		US3916899
		US3923426
		US3987790
		US3995631
		US4016880
		US4036228
		US4111202
		US4111203
		US4203440
		US4203442
		US4210139
		US4327725
		US4627850
		US4865845
		US5057318
		US5059423
		US5112614
		US5137727
		US5234692
		US5234693
		US4350155
		US5443450
		US5814019
		US5976109
		US6017328
		US6171276
		US6241704
		US6464687
		US6475180
		US6512954
		WO02089731
		WO2005032329
		WO2009148541
		WO2006133326
		WO2008021928
		WO2007018692
		US2006199174
		US2008118511
		US2007065427
		US2007122378
		US5503973
		US5876920
		US6159939
		US6627610
		US7342016
		US5874442
		US7101897
		US6232338
		US4211771
		US6277830
		US5559101
	US6423695
	US2002058635
	WO0190121
	WO02069903
	WO02057287
	WO02057425
	US6642204
	US6534523
	US6420380
	US6410531
	US6329417
	US6329379
	US6323180
	US6143715
	US6608027
	US6617309
	US6608067
	US6265380
	US6624290
	US5990276
	WO9907733
	WO9907734
	WO0009558
	WO0009543
	WO0059929
	WO02060926
	US2003019067
	US2003187018
	US2003186895
	US6479508
	US6440985
	WO0147883
	WO02100846
	WO02100851
	WO0185172
	WO02098424
	WO0006529
	WO0206246
	WO03000254
	EP1256628
	US4695623
	US4897471
	US5382657
	US5981709
	US5951974
	US2010028299
	- ANNALS INTERNAL MED, (2000), vol. 132, pages 296 - 305
	- CURR TOP MICROBIOL IMMUNOL, (2000), vol. 242, pages 55 - 84
	- J VIROL, (2002), vol. 76, pages 5974 - 5984
	- J VIROL, (2004), vol. 78, pages 11393 - 11400
	- "Drug Latentiation", HARPER, N.J., Progress in Drug Research, (1962), vol. 4, pages 221 - 294
	- WANG ET AL., "Prodrug approaches to the improved delivery of peptide drug", CURR. PHARM. DESIGN, (1999), vol. 5, no. 4, pages 265 - 287
	- PAULETTI ET AL., "Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies", ADV. DRUG. DELIVERY REV., (1997), vol. 27, pages 235 - 256
	- MIZEN ET AL., "The Use of Esters as Prodrugs for Oral Delivery of P-Lactam antibiotics", PHARM. BIOTECH, (1998), vol. 11, pages 345 - 365
	- GAIGNAULT ET AL., "Designing Prodrugs and Bioprecursors I. Carrier Prodrugs", PRACT. MED. CHEM, (1996), pages 671 - 696
	- M. ASGHARNEJAD, "Improving Oral Drug Transport Via Prodrugs", TRANSPORT PROCESSES IN PHARMACEUTICAL SYSTEMS, (2000), pages 185 - 218
	- BALANT ET AL., "Prodrugs for the improvement of drug absorption via different routes of administration", EUR. J. DRUG METAB. PHARMACOKINET, (1990), vol. 15, no. 2, pages 143 - 53
	- BALIMANE; SINKO, "Involvement of multiple transporters in the oral absorption of nucleoside analogues", ADV. DRUG DELIVERY REV., (1999), vol. 39, no. 1-3, pages 183 - 209
	- BROWNE, "Fosphenytoin (Cerebyx", CLIN. NEUROPHARMACOL, (1997), vol. 20, no. 1, pages 1 - 12
	- BUNDGAARD, "Bioreversible derivatization of drugs--principle and applicability to improve the therapeutic effects of drugs", ARCH. PHARM. CHEMI, (1979), vol. 86, no. 1, pages 1 - 39
	- FLEISHER ET AL., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADV. DRUG DELIVERY REV, (1996), vol. 19, no. 2, pages 115 - 130
	- FLEISHER ET AL., "Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting", METHODS ENZYMOL., (1985), vol. 112, pages 360 - 81
	- FARQUHAR D ET AL., "Biologically Reversible Phosphate-Protective Groups", J. PHARM. SCI., (1983), vol. 72, no. 3, pages 324 - 325
	- HAN, H.K ET AL., "Targeted prodrug design to optimize drug delivery", AAPS PHARMSCI., (2000), vol. 2, no. 1, page E6
	- SADZUKA Y, "Effective prodrug liposome and conversion to active metabolite", CURR. DRUG METAB, (2000), vol. 1, no. 1, pages 31 - 48
	- D.M. LAMBERT, "Rationale and applications of lipids as prodrug carriers", EUR. J. PHARM. SCI., (2000), vol. 11, no. 2, pages 15 - 27
	- WANG, W ET AL., "Prodrug approaches to the improved delivery of peptide drugs", CURR. PHARM. DES., (1999), vol. 5, no. 4, pages 265 - 87
	- CURRENT OPINION IN INVESTIGATIONAL DRUGS, (2006), vol. 7, no. 2, pages 109 - 117
	- J. MED. CHEM., (2008), vol. 51, pages 2328 - 2345
	- NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, (2005), vol. 24, no. 5 - 7, pages 375 - 381
	- GRETCH ET AL., ANN. INTERN. MED., (1995), vol. 123, pages 321 - 329
	- VARGO ET AL., TRANSFUSION, (2002), vol. 42, pages 876 - 885
	- PEARLSTEIN ET AL., J. MED. CHEM., (2003), vol. 46, no. 11, pages 2017 - 2022
	- FERMINI ET AL., ANNUAL REPORTS IN MEDICINAL CHEMISTRY, (2004), vol. 39, page 323
	- ., Synthetic Organic Chemistry, JOHN WILEY & SONS, INC.
	- LAROCK, R. C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2nd Edition, WILEY-VCH, (1999), ISBN 0-471-19031-4
	- MARCH, J., Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 4th Edition, JOHN WILEY & SONS, (1992), ISBN 0-471-60180-2
	- OTERA, J., Modem Carbonyl Chemistry, WILEY-VCH, (2000), ISBN 3-527-29871-1
	- PATAI, S., Patai's 1992 Guide to the Chemistry of Functional Groups, (1992), ISBN 0-471-93022-9
	- SOLOMONS, T. W. G, Organic Chemistry 7th Edition, JOHN WILEY & SONS, (2000), ISBN 0-471-19095-0
	- STOWELL, J.C., Intermediate Organic Chemistry 2nd Edition, WILEY, (1993), ISBN 0-471-57456-2
	- Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia, JOHN WILEY & SONS, (1999), ISBN 3-527-29645-X
	- ., Chemistry of Functional Groups, JOHN WILEY & SONS
	- ROTH, T. ET, J. MED CHEM., (1997), vol. 40, no. 26, page 4199
	- ZHANG, P. ET AL., TET. LETT., (2007), vol. 48, page 8659
	- SEFTON, CRC CRIT. REF. BIOMED. ENG, (1987), vol. 14, page 201
	- BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
	- SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
	- LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
	- BRUNT, HEPATOL., (2000), vol. 31, pages 241 - 246
	- METAVIR, HEPATOLOGY, (1994), vol. 20, pages 15 - 20
	- KNODELL, HEPATOL, (1981), vol. 1, page 431
	- SCHEUER, J. HEPATOL., (1991), vol. 13, page 372
	- ISHAK, J. HEPATOL., (1995), vol. 22, pages 696 - 699
	- PAUSE ET AL., J. BIOL. CHEM., (2003), vol. 278, pages 20374 - 20380
	- LAMARRE ET AL., HEPATOLOGY, (2002), vol. 36, page 301A
	- ZHONG ET AL., ANTIMICROB. AGENTS CHEMOTHER., (2003), vol. 47, pages 2674 - 2681
	- DHANAK ET AL., J. BIOL CHEM., (2002), vol. 277, no. 41, pages 38322 - 7
	- OSBORN ET AL., J. PHARMACOL. EXP. THERAP., (2002), vol. 303, pages 540 - 548
	- MASCI ET AL., CURR. ONCOL. REP., (2003), vol. 5, pages 108 - 113
	- NATURE BIOTECHNOLOGY, (2008), vol. 26, pages 1019 - 1027
	- BLIGHT ET AL., J. VIROL., (2002), vol. 76, page 13001
	- ZHANG ET AL., J. VIROL., (2004), vol. 78, page 1448
	- ELAZAR ET AL., J. VIROL., (2003), vol. 77, no. 10, pages 6055 - 61
	US20070844993
	US20080057188
	WO2002CA01127
	WO2002CA01128
	WO2002CA01129

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p